Publications and Posters – Aridis Pharmaceuticals Investors Relation

Posters

Safety and Efficacy of Salvecin (AR-301), a Human Monoclonal Antibody, in Patients with Severe Pneumonia Caused by S. aureus, a Phase 2 Study

Publications

Investor Presentation

Analysts Fireside Chat 2020 Fireside Chat Vimeo link

Aridis COVID-19 slides Cantor Fireside Chat Cantor Fireside Video chat link

Aridis COVID-19 slides Maxim Conference

APEXTM Technology Presentation

Safety and tolerability of a single administration of AR 301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first in human trial

Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia

Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia

Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes

Pharmacokinetics and Safety Profile of the Human Anti-Pseudomonas aeruginosa Serotype O11 Immunoglobulin M Monoclonal Antibody KBPA-101 in Healthy Volunteers

Aridis Pharmaceuticals Inc.

983 University Avenue Suite B
Los Gatos, CA 95032
Phone: 408-385-1742
Fax: 408-356-9548

INVESTORS

CONNECT US